Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

Table 3 Univariate survival analysis of prognostic factors of NSCLC (n = 42)

Variables	n	Median survival (95% CI) (days)	P
Age (years)
<60	27	370.0 (301.3-438.7)	0.665
≥ 60	15	333.0 (244.6-421.4)
Stage
III	23	416.0 (369.1-462.8)	0.163
IV	19	327. 0 (298.7-355.3)
T factor
T2-T3	17	431.0 (315.3-546.7)	0.051
T4	25	348.0 (248.3-447.6)
N factor
N0-N1	21	394.0 (312.2-475.8)	0.380
N2-N3	21	348.0 (310.1-385.9)
ECOG
1	30	403.0 (327.9-478.0)	0.130
2-3	12	333.0 (311.5-354.5)
Histology
SCC	31	367.0 (288.1-445.9)	0.270
ADC	11	394.0 (324.8-463.1)
Smoking habit
Smokers	36	370.0 (294.0-446.0)	0.745
Non-smokers	06	367.0 (248.7-485.3)
Tobacco habit
Yes	08	394.0 (352.3-435.6)	0.022
No	34	314.0 (266.0-362.0)
Plasma VEGF (median)
<275.2 pg/mL	21	348.0 (246.1-449.9)	0.885
≥ 275.2 pg/mL	21	370.0 (288.3-451.7)

T, tumor; N, nodal status; ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor; 95% CI, 95% confidence interval.